It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solu ...

It has been about a month since the last earnings report for IQVIA Holdings (IQV) . Shares have added about 3.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. IQVIA Surpasses Q2 Earnings Estimates IQVIA Holdin ...

I I F ■ F Matteo Colombo Investment update Following my May publication on IQVIA Holdings Inc. (NYSE:IQV) the stock is +5%, marking a 28% return since I first rated the business investment-grade back in Jan '21. This is a business I know tremendously well, having analyzed its credentials for more than 3 years and owned the stock for our equity budget for that entire duration. In the five publications I've made on IQV here on SA since then, my views have not changed on this long-term compounder. Following it ...

Shares of IQVIA Holdings Inc. (IQV) have risen 12% over the past year, outperforming the 10% growth of the industry it belongs to. Image Source: Zacks Investment Research The company has an expected long-term (three to five years) EPS growth rate of 10.4%. Its earnings for 2024 and 2025 are anticipated to grow 9.5% and 11%, respectively, year over year. Factors That Bode Well IQVIA's top line is bolstered by the strong segmental performance.The Technology & Analytics Solutions ("TAS") segment delivered a 4% ...

In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a company's dependence on overseas markets, as this offers a window into the company's earnings stability, its ability to benefit from varied economic cycles and its potential for long-term growth. Participation in global economies acts as a defense against economic difficulties at home and a pathway ...

Core Viewpoint - Investors are evaluating IQVIA Holdings (IQV) and Waters (WAT) for potential undervalued stock opportunities, with IQV currently appearing as the more favorable option based on various valuation metrics [1]. Valuation Metrics - IQV has a forward P/E ratio of 22.16, while WAT has a higher forward P/E of 25.97, indicating that IQV may be more attractively priced [3]. - The PEG ratio for IQV is 2.05, compared to WAT's PEG ratio of 4.90, suggesting that IQV's expected earnings growth is more reasonably priced [3]. - IQV holds a Value grade of B, while WAT has a Value grade of D, reflecting stronger estimate revision activity and more attractive valuation metrics for IQV [4]. Zacks Rank and Style Scores - IQV has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while WAT has a Zacks Rank of 4 (Sell) [2]. - The Zacks Rank system favors stocks with strong earnings estimate revisions, and combining this with a strong Value grade can help identify great value stocks [5]. Additional Valuation Comparisons - IQV's P/B ratio is 6.65, significantly lower than WAT's P/B ratio of 14.50, further indicating that IQV may be undervalued relative to its book value [6]. - The Value category of the Style Scores system utilizes various metrics, including P/E ratio, P/S ratio, earnings yield, and cash flow per share, to assess a company's fair value [7].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35907 _____________________________________________________ ...

Life sciences clinical researcher IQVIA's second-quarter results beat analysts' expectations for revenue and net income. The company also raised its full-year guidance. IQVIA said its technology and analytics products were major growth drivers. IQVIA's stock rose nearly 7% in intraday trading Monday to move into positive territory for the year. Growth Driven by Technology & Analytics Solutions Unit Looking ahead, IQVIA narrowed its full-year revenue guidance to a range of $15.43 billion to $15.53 billion fr ...

Company Performance - IQV stock has gained 5.2% over the past six months, outperforming the industry rally of 2.9% [1] - IQVIA Holdings Analytics Inc. reported impressive second-quarter 2024 results, with earnings and revenues surpassing the Zacks Consensus Estimate [12] - Adjusted earnings were $2.6 per share, exceeding the Zacks Consensus Estimate by 2.3% and increasing 2.4% year-over-year [6] - Total revenues reached $3.8 billion, slightly surpassing the consensus estimate and rising 2.3% from the previous year [6] - Adjusted EBITDA for the second quarter was $887 million, indicating a 12.7% growth from the year-ago quarter [8] Revenue Segments - Research and Development segment revenues were $2.2 billion, increasing 2.4% from the year-ago quarter and 3.3% on a constant-currency basis, surpassing the estimate of $2.1 billion [2] - Technology and Analytics segment revenues were $1.5 billion, increasing 2.7% from the second quarter of 2023, meeting the estimate and increasing 3.8% on a constant-currency basis [7] - Contract Sales & Medical Solutions revenues declined 2.3% year-over-year to $172 million, missing the estimate of $177 million but increasing 2.8% on a constant-currency basis [13] Financial Position - The company exited the quarter with cash and cash equivalents of $1.5 billion, up from $1.4 billion at the end of the previous quarter [3] - Long-term debt decreased to $12.1 billion from $12.8 billion at the end of the first quarter of 2024 [3] - Net cash generated from operating activities was $588 million, with capital expenditure of $143 million, resulting in a free cash flow of $445 million for the quarter [14] Guidance - For 2024, IQV updated its revenue guidance to $15.43-$15.53 billion, with the mid-point of $15.48 billion higher than the Zacks Consensus Estimate of $15.44 billion [4] - The adjusted EPS guidance was raised to $11.10-$11.30, compared to the previous range of $10.95-$11.25, with the Zacks Consensus Estimate at $11.07 [15] - The updated guided range for adjusted EBITDA is anticipated to be $3.71-$3.77 billion, compared to the previous range of $3.70-$3.80 billion [15]